Search results for "recurrence"

showing 10 items of 1036 documents

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

2016

We report the outcome of 30 consecutive patients with Hodgkin disease (HD) who underwent single-unit UCBT. Most (90%) patients had failed previous autologous hematopoietic stem cell transplantation. The conditioning regimens were based on combinations of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin. The cumulative incidence (CI) of myeloid engraftment was 90% [95% confidence interval (C.I.), 74-98%] with a median of 18 d (range, 10-48). CI of acute graft-versus-host disease (GvHD) grades II-IV was 30% (95% C.I., 17-44%), while the incidence of chronic GVHD was 42% (95% C.I., 23-77%). The non-relapse mortality (NRM) at 100 d and 4 yr was 30% (95% C.I., 13-4…

MaleHerpesvirus 4 HumanTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceHodgkin's lymphomaIncidence (epidemiology)Graft Survivalumbilical cord blood transplantationHematologyGeneral MedicineMiddle AgedHodgkin DiseaseFludarabine030220 oncology & carcinogenesisAcute DiseaseFemaleCord Blood Stem Cell TransplantationVidarabinemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideThioTEPA03 medical and health sciencesInternal medicinemedicineHumansInfectious MononucleosisBusulfanCyclophosphamideAntilymphocyte Serumbusiness.industryMyeloablative AgonistsHodgkin's lymphomamedicine.diseaseSurvival AnalysisSurgeryEBV post-transplant lymphoproliferative diseaseChronic DiseaseEBV post-transplant lymphoproliferative disease; Hodgkin's disease; Hodgkin's lymphoma; umbilical cord blood transplantationHodgkin's diseasebusinessSettore MED/15 - Malattie del SangueThiotepaBusulfan030215 immunologyEuropean Journal of Haematology
researchProduct

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual…

2014

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

MaleHistologyIntegrin alpha4Antigens CD19Plasma CellsAntineoplastic AgentsSettore MED/42 - Igiene Generale E ApplicataImmunophenotypingMonoclonal gammopathieRecurrenceMultiple myelomaHumansAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleMonoclonal gammopathies; Multiparameter flow cytometry; Multiple myeloma; Cell Biology; HistologyCell BiologyMiddle AgedCD58 AntigensFlow CytometryPrognosisCD56 AntigenClone CellsMultiparameter flow cytometryTreatment OutcomeGene Expression RegulationLeukocyte Common AntigensRegression AnalysisFemaleBiomarkers
researchProduct

Benign multicystic mesothelioma: A case report of recurrent disease in a young adult with familiarity for renal cell carcinoma

2019

Benign multi-cystic peritoneal mesothelioma (BMCM) is a very rare disease (about 150 cases observed). The aetiology is currently little-known, and the data collected, without having achieved conclusive re sults, identify two possible causes: neoplastic and reactive inflammatory. This case report refers to a recidivism of BCMC in a patient whose brother, few months before, underwent a left nephrectomy and right renal Radio Frequency Termo Ablation (RFTA) for bilateral papillary renal cell carcinoma. For the recurring trend, the onset in a male young patient without chronic inflammatory diseases evidence, the presence of a first degree relative with a rare carcinoma we supposed a neoplastic a…

MaleHumansMesothelioma CysticMiddle AgedNeoplasm Recurrence Localbenign multcystic mesotheliom renal cells kideny tumor familiarity oncologyCarcinoma Renal CellKidney NeoplasmsPeritoneal Neoplasms
researchProduct

Pseudotumoral cystitis cystica of the urethra in a boy

1997

MaleHyperplasiaCystsbusiness.industryUrologyAnatomyMale urethraUrinary IncontinenceUrethramedicine.anatomical_structureRecurrenceCystitisUrethral DiseasesCystitis cysticamedicineHumansChildbusinessBJU International
researchProduct

Mutant K-ras2 in serum

2003

Mutant tumour derived DNA has been detected in the sera of colorectal cancer patients. We investigated if mutant serum KRAS2 was detectable preoperatively in a large group of patients with colorectal neoplasia. A prospective study of 94 patients who underwent putative curative resection for colorectal carcinoma (CRC) was performed to ascertain if serum mutant KRAS2 could be used postoperatively as a disease marker.Preoperative sera from 78 patients were analysed (group A). Sera from 94 patients were obtained three monthly for up to three years during the postoperative period (group B). Codon 12 and 13 KRAS2 mutations were analysed in matched tumour and serum samples.In the preoperative grou…

MaleLetterColorectal cancervirusesMutantDNA Mutational AnalysisBioinformaticsProto-Oncogene Proteins p21(ras)03 medical and health sciencesCollaborative group0302 clinical medicineProto-Oncogene ProteinsMedicineHumansRas2neoplasmsGene030304 developmental biologyAged0303 health sciencesbusiness.industryPoint mutationGastroenterologyDNA NeoplasmMiddle Agedmedicine.diseasePrognosis3. Good healthProto-Oncogene Proteins p21(ras)Molecular analysisCarcinoembryonic AntigenEpidemiologic Studies030220 oncology & carcinogenesisCancer researchras ProteinsFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsBiomarkers
researchProduct

Orthodontic treatment stability predictors: A retrospective longitudinal study

2016

ABSTRACTObjective: To examine medium- to long-term orthodontic treatment stability and its possible association with certain variables.Materials and Methods: In a retrospective longitudinal study of 70 postretention patients, the Peer Assessment Rating (PAR) index was measured at the start (T1) and end (T2) of treatment and between 4 and 10 years afterwards (T3). The stability was considered absolute when the T2 and T3 values were identical and relative when the difference was within the ±5 range.Results: Among the 70 patients, 65.8% were female and 34.2% were male. Their mean age was 14.5 years. The mean treatment length was 2.4 years. The mean retention phase was 3.3 years. The mean pre- …

MaleLongitudinal studyTime FactorsAdolescentTreatment outcomeDentistryOrthodonticsOverbiteOrthodontics Corrective03 medical and health sciences0302 clinical medicineRecurrenceHumansMedicineLongitudinal StudiesLettersRetrospective StudiesLower anteriorbusiness.industryFollow up studiesMean age030206 dentistryOriginal ArticlesRelative stabilityTreatment OutcomeFemaleAbsolute stabilitybusinessOrthodontic RetainersMalocclusion030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Persistent offenders and adolescence-limited offenders: Differences in life-courses.

2020

Background and Aims As our previous study indicated, almost half of juvenile delinquents continued offending in adulthood, while the rest ceased to do so. We compared these groups with each other and with non‐offenders in the life‐course use of alcohol, identity development and life situation. Methods Based on the Jyväskylä Longitudinal Study of Personality and Social Development, four groups were formed at age 42 for men and women: persistent, adolescence‐limited and adult‐onset offenders and non‐offenders. Longitudinal data (N = 369; 53% males) have been collected at ages 8, 14, 20, 27, 36, 42 and 50. Results Persistent offending, but not adolescence‐limited offending, was associated with…

MaleLongitudinal studynuorisorikollisuusPersonality AssessmentRecurrenceJuvenile delinquencyMedicineLongitudinal StudiesChildidentitymedia_commonoffenderself‐control05 social sciencesGeneral MedicineSelf-controlAntisocial Personality DisorderMiddle AgedPsychiatry and Mental healthWorkforceJuvenile DelinquencyLife course approachFemalePsychology (miscellaneous)Crimealkoholinkäyttölife‐course050104 developmental & child psychologyPersonalityAdultAdolescentmedia_common.quotation_subjectkeski-ikädrinking behavioursosiaalinen identiteettirikoksentekijätViolenceelämänkaariPathology and Forensic MedicineYoung AdultPersonalityHumans0501 psychology and cognitive sciencesmiddle age0505 lawPovertybusiness.industryCriminalsMiddle ageongelmakäyttäytyminen050501 criminologynuoruusbusinessDemographyCriminal behaviour and mental health : CBMHREFERENCES
researchProduct

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

2015

Background: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC.Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'.Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed. After a medi…

MaleLung NeoplasmsENSATGastroenterologyPROPOSALClinical endpointAdrenocortical carcinomaENDOCRINEStage (cooking)Liver NeoplasmsIntraventricular blockHematologyMiddle AgedSERIESCANCEREuropeSurvival RateOncologymedicine.veinLymphatic MetastasisSURVIVALFemalemedicine.medical_specialtyUNITED-STATESBone NeoplasmsInferior vena cavaInternal medicineGRASmedicineadrenocortical carcinomaPrognostic factors adrenocortical carcinomaHumansNeoplasm InvasivenessSurvival rateAdrenocortical carcinoma; ENSAT; GRAS; Prognostic factors; Oncology; HematologyNeoplasm StagingRetrospective Studiesbusiness.industryCancerprognostic factorsRetrospective cohort studymedicine.diseaseAdrenal Cortex NeoplasmsSurgeryAdrenocortical carcinoma prognosisprognosisNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

2006

International audience; The confrontation of the macro- and micro-economic approaches of hospital costs is a recurrent question, in particular for pathologies where length of stay is highly variable, like acute myeloid leukemias (AML). This monocentric and retrospective study compares direct hospital medical costs of induction and relapse treatment sequences for AML, valued according to four different approaches: the analytic accounting system of our hospital, the French Diagnosis Related Group (DRG) cost databases of hospital discharges (readjusted, or not, to actual hospital stay duration), and official tariffs from the new French DRG prospective payment system. The average cost of hospit…

MaleMESH: Remission InductionMESH : Retrospective StudiesMESH : RecurrenceMESH: Leukemia MyeloidMESH: Length of StayRecurrence[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : FemaleHospital Costshealth care economics and organizationsMESH: Diagnosis-Related GroupsMESH: Hospital CostsMESH: Middle AgedRemission InductionMESH : Acute DiseaseMiddle AgedMESH : AdultMESH : Diagnosis-Related GroupsMESH : Length of StayLeukemia MyeloidAcute DiseaseMESH : Leukemia MyeloidMESH: Acute Disease[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMESH : Prospective Payment SystemFranceAdultAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : MaleMESH : Hospital CostsMESH: Prospective Payment SystemMESH : AdolescentHumansMESH : Middle AgedMESH : FranceDiagnosis-Related GroupsRetrospective StudiesMESH: AdolescentMESH : Remission InductionMESH: HumansProspective Payment SystemMESH : HumansMESH: Retrospective StudiesMESH: AdultLength of StayMESH: MaleMESH: RecurrenceMESH: FranceMESH: Female
researchProduct

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy

2008

Summary We report that a recently developed combined immunotherapy (CIT) has the capacity to prevent a spontaneous relapse of replicating Mycobacterium tuberculosis bacilli in the lungs of BALB/c, C57Bl/6 or C3H/HeJ strains of mice, following 4 weeks of non-sterilising treatment with isoniazid and rifampicin. The CIT regimen, represented by recombinant IFNγ, anti-α crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy. Although CIT enhanced lung granuloma area, nitric oxide, cytoki…

MaleMicrobiology (medical)TuberculosisTuberculosiAntibodiemedicine.medical_treatmentImmunologyAntitubercular AgentsColony Count MicrobialMicrobiologyAntibodiesMycobacterium tuberculosisInterferon-gammaMiceAdjuvants ImmunologicRecurrencemedicineAnimalsalpha-CrystallinsRelapseTuberculosis PulmonaryCytokineMice Inbred BALB CMice Inbred C3HChemotherapyLungbiologybusiness.industryTuberculosis; Cytokines; Antibodies; Immunotherapy; RelapseIsoniazidMycobacterium tuberculosisImmunotherapybiology.organism_classificationmedicine.diseaseCombined Modality TherapyRecombinant ProteinsImmunoglobulin AMice Inbred C57BLRegimenInfectious Diseasesmedicine.anatomical_structureModels AnimalImmunologyInterleukin-4ImmunotherapybusinessRifampicinmedicine.drugTuberculosis
researchProduct